caa a22 4500 465789463 CHVBK 20180323112019.0 cr unu---uuuuu 170327e19900201xx s 000 0 eng 10.1007/BF00216938 doi (NATIONALLICENCE)springer-10.1007/BF00216938 A phase II trial of peg-L-asparaginase in the treatment of non-hodgkins lymphoma [Elektronische Daten] [Hyman Muss, Nancy Spell, Diane Scudiery, Robert Capizzi, M. Cooper, Julia Cruz, Don Jackson, Frederick Richards II, Charles Spurr, Douglas White, Patricia Zekan, Anita Franklin] Summary: A polyethylene glycol conjugate of L-asparaginase (PEGLA) was administered to 21 patients with refractory non-Hodgkin's lymphoma. The dose given was 2,000 u/m2 intramuscularly every 2 weeks. Eligibility required at least one prior trial of chemotherapy and ambulatory performance status. At entry, all patients had measurable lesions and documented disease progression. The median age of the patients was 61 years; 18 (86%) were ambulatory with minimal symptoms, 12 patients (57%) had 3 or more prior regimens, and 13 (62%) had stage IV disease. Histologic subtype was low grade in 11 patients (52%), intermediate in 7 (33%), high grade in 2 (10%) and unclassifiable in one (5%). There were two partial responses (11%) noted (95% confidence interval of response of 1-30%). Eleven patients (52%) were removed from study due to disease progression. Nine patients (43%), required removal for toxicity (7 for protracted nausea and vomiting and 2 for confusion). One patient died of sepsis while on study but this was not considered drug related. Almost one third of patients complained of fatigue or loss of appetite. Nausea and vomiting occurred in approximately half the patients and was moderate to severe in 9. Diarrhea and abdominal pain were also noted in onethird of those treated. Changes in the partial thromboplastin time and fibrinogen were noted in most patients but resulted in no bleeding complications. In this trial, PEGLA displayed modest activity in a heterogenous group of patients with progressive non-Hodgkin's lymphoma. Kluwer Academic Publishers, 1990 lymphoma nationallicence asparaginase nationallicence polyethylene glycol nationallicence Phase II trial nationallicence Muss Hyman The Cancer Center of Wake Forest University Bowman Gray School of Medicine, Winston-Salem, North Carolina aut Spell Nancy The Cancer Center of Wake Forest University Bowman Gray School of Medicine, Winston-Salem, North Carolina aut Scudiery Diane The Cancer Center of Wake Forest University Bowman Gray School of Medicine, Winston-Salem, North Carolina aut Capizzi Robert The Cancer Center of Wake Forest University Bowman Gray School of Medicine, Winston-Salem, North Carolina aut Cooper M. The Cancer Center of Wake Forest University Bowman Gray School of Medicine, Winston-Salem, North Carolina aut Cruz Julia The Cancer Center of Wake Forest University Bowman Gray School of Medicine, Winston-Salem, North Carolina aut Jackson Don The Cancer Center of Wake Forest University Bowman Gray School of Medicine, Winston-Salem, North Carolina aut Richards II Frederick The Cancer Center of Wake Forest University Bowman Gray School of Medicine, Winston-Salem, North Carolina aut Spurr Charles The Cancer Center of Wake Forest University Bowman Gray School of Medicine, Winston-Salem, North Carolina aut White Douglas The Cancer Center of Wake Forest University Bowman Gray School of Medicine, Winston-Salem, North Carolina aut Zekan Patricia The Cancer Center of Wake Forest University Bowman Gray School of Medicine, Winston-Salem, North Carolina aut Franklin Anita The Cancer Center of Wake Forest University Bowman Gray School of Medicine, Winston-Salem, North Carolina aut Investigational New Drugs Kluwer Academic Publishers 8/1(1990-02-01), 125-130 0167-6997 8:1<125 1990 8 10637 https://doi.org/10.1007/BF00216938 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00216938 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Muss Hyman The Cancer Center of Wake Forest University Bowman Gray School of Medicine, Winston-Salem, North Carolina aut NATIONALLICENCE 700 1- Spell Nancy The Cancer Center of Wake Forest University Bowman Gray School of Medicine, Winston-Salem, North Carolina aut NATIONALLICENCE 700 1- Scudiery Diane The Cancer Center of Wake Forest University Bowman Gray School of Medicine, Winston-Salem, North Carolina aut NATIONALLICENCE 700 1- Capizzi Robert The Cancer Center of Wake Forest University Bowman Gray School of Medicine, Winston-Salem, North Carolina aut NATIONALLICENCE 700 1- Cooper M. The Cancer Center of Wake Forest University Bowman Gray School of Medicine, Winston-Salem, North Carolina aut NATIONALLICENCE 700 1- Cruz Julia The Cancer Center of Wake Forest University Bowman Gray School of Medicine, Winston-Salem, North Carolina aut NATIONALLICENCE 700 1- Jackson Don The Cancer Center of Wake Forest University Bowman Gray School of Medicine, Winston-Salem, North Carolina aut NATIONALLICENCE 700 1- Richards II Frederick The Cancer Center of Wake Forest University Bowman Gray School of Medicine, Winston-Salem, North Carolina aut NATIONALLICENCE 700 1- Spurr Charles The Cancer Center of Wake Forest University Bowman Gray School of Medicine, Winston-Salem, North Carolina aut NATIONALLICENCE 700 1- White Douglas The Cancer Center of Wake Forest University Bowman Gray School of Medicine, Winston-Salem, North Carolina aut NATIONALLICENCE 700 1- Zekan Patricia The Cancer Center of Wake Forest University Bowman Gray School of Medicine, Winston-Salem, North Carolina aut NATIONALLICENCE 700 1- Franklin Anita The Cancer Center of Wake Forest University Bowman Gray School of Medicine, Winston-Salem, North Carolina aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/1(1990-02-01), 125-130 0167-6997 8:1<125 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer